Vancomycin assay performance in patients with end-stage renal disease receiving hemodialysis

Joanna R. Kingery, Kevin M. Sowinski, Michael A. Kraus, James E. Klaunig, Bruce A. Mueller

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

Study Objective. To compare the performance of polyclonal fluorescence polarization immunoassay (pFPIA) with that of enzyme-multiplied immunoassay technique (EMIT) in patients receiving vancomycin and hemodialysis. Setting. Outpatient hemodialysis center. Patients. Seven subjects with end-stage renal disease treated with hemodialysis 3 times/week with a cellulose triacetate hemodialyzer. Intervention. Subjects received vancomycin 1000 mg intradialytically during the first study session and 750 mg every other hemodialysis session thereafter for 4 weeks. Measurements and Main Results. Blood samples were obtained throughout the study, and vancomycin serum concentrations were determined by pFPIA and EMIT. The mean ± SD difference (estimate of bias) between assays was -1.10 ± 1.35 mg/L. The limits of agreement (mean difference ± 1.96 · SD) between them were -3.80-1.60 mg/L. Conclusion. Our data suggest that the manufacturer's changes in the vancomycin pFPIA eliminated overestimation of drug concentrations in patients undergoing high-permeability hemodialysis.

Original languageEnglish (US)
Pages (from-to)653-656
Number of pages4
JournalPharmacotherapy
Volume20
Issue number6 I
DOIs
StatePublished - Jan 1 2000

ASJC Scopus subject areas

  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Vancomycin assay performance in patients with end-stage renal disease receiving hemodialysis'. Together they form a unique fingerprint.

  • Cite this

    Kingery, J. R., Sowinski, K. M., Kraus, M. A., Klaunig, J. E., & Mueller, B. A. (2000). Vancomycin assay performance in patients with end-stage renal disease receiving hemodialysis. Pharmacotherapy, 20(6 I), 653-656. https://doi.org/10.1592/phco.20.7.653.35177